STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

Marjolaine Debant, Miguel Burgos, Patrice Hemon, Paul Buscaglia, Tinhinane Fali, Sarra Melayah, Nelig Le Goux, Christophe Vandier, Marie Potier-Cartereau, Jacques-Olivier Pers, Adrian Tempescul, Christian Berthou, Cristina Bagacean, Olivier Mignen, and Yves Renaudineau

Abstract

Background: Dysregulation in calcium (Ca^{2+}) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca^{2+} pathway has been associated with disease progression, the importance of the newly described constitutive Ca^{2+} entry (CE) pathway is less clear. In addition, we hypothesized that these differences reflect modifications of the CE pathway and Ca^{2+} actors such as Orai1, transient receptor potential canonical (TRPC) 1, and stromal interaction molecule 1 (STIM1), the latter being the focus of this study.

Methods: An extensive analysis of the Ca^{2+} entry (CE) pathway in CLL B cells was performed including constitutive Ca^{2+} entry, basal Ca^{2+} levels, and store operated Ca^{2+} entry (SOCE) activated following B cell receptor engagement or using Thapsigargin. The molecular characterization of the calcium channels Orai1 and TRPC1 and their partner STIM1 was performed by flow cytometry and/or Western blotting. Specific siRNAs for Orai1, TRPC1 and STIM1 plus the Orai1 channel blocker Synta66 were used. CLL B cell viability was tested in the presence of an anti-STIM1 monoclonal antibody (mAb, clone GOK) coupled or not with an anti-CD20 mAb, rituximab. The Cox regression model was used to determine the optimal threshold and to stratify patients.

Results: Seeking to explore the CE pathway, we found in untreated CLL patients that an abnormal CE pathway was (i) highly associated with the disease outcome; (ii) positively correlated with basal Ca^{2+} concentrations; (iii) independent from the BCR-PLCγ2-InsP3R(SOCE)Ca^{2+} signaling pathway; (iv) supported by Orai1 and TRPC1 channels; (v) regulated by the pool of STIM1 located in the plasma membrane (STIM1_{PM}); and (vi) blocked when using a mAb targeting STIM1_{PM}. We further established an association between an elevated expression of STIM1_{PM} and clinical outcome. In addition, combining an anti-STIM1 mAb with rituximab significantly reduced in vitro CLL B cell viability within the high STIM1_{PM} CLL subgroup.

Conclusions: These data establish the critical role of a newly discovered BCR independent Ca^{2+} entry in CLL evolution, provide new insights into CLL pathophysiology, and support innovative therapeutic perspectives such as targeting STIM1 located at the plasma membrane.

Keywords: CLL, STIM1, Constitutive Ca^{2+} entry, Disease outcome
**Background**

Chronic lymphocytic leukemia (CLL) is characterized by a heterogeneous natural history that is partly predicted by clinical, epigenetic and genetic features [1]. In addition, there is long standing evidence that CLL B cells (B-CLL) present an altered calcium (Ca^{2+}) signaling pathway, which evolves with disease progression [2, 3]. Induction of the Ca^{2+} signaling pathway in B cells is thought to follow the model in which BCR interaction with the antigen results in the formation of the signalosome consisting of an active complex composed of spleen tyrosine kinase (Syk), B-cell linker protein (BLNK), Bruton-tyrosine-kinase (BTK), phospholipase C gamma 2 (PLCy2), and phosphatidylinositol-4,5-bisphosphate 3-kinase δ (PI3Kδ) (Additional file 1: Figure S1A). Signalosome activation cleaves the membrane phospholipid phosphatidyl inositol 4,5-biphosphate (InsP2) into diacylglycerol (DAG) and inositol 1,4,5-triphosphate (InsP3), which subsequently, through binding to the endoplasmic reticulum (ER) IP3 receptor (InsP3R), mobilizes initially Ca^{2+} from stores and secondarily extracellular Ca^{2+} [4]. The reticular stromal interaction molecule 1 (STIM1) and plasma-membrane Orai1 channel are believed to be the main molecular actors of store operated Ca^{2+} entry (SOCE) in lymphocytes [5–8]. Finally, an increase in Ca^{2+} entry following B cell receptor (BCR) engagement leads to cellular metabolic changes, cell survival, proliferation, differentiation, migration, antibody production and, at very high concentrations, apoptosis [9–12].

At first glance, CLL cases with indolent and stable disease present B cells that are ineffective at mobilizing Ca^{2+} after BCR cross-linking, thus resembling B cells anergized in vivo after chronic antigenic stimulation [13]. For these patients, B-CLL cell incapacity to mobilize Ca^{2+} was related to mutated IgHV status and an elevated level of CD38, apoptosis due to an internal epitope present in the second IgHV framework of stereotyped B cells in B-CLL cells such as a BCR autonomous signaling capacity [14]. However, other processes are described in order to provide alternative explanations for Ca^{2+} dysregulation in B-CLL cells such as a BCR autonomous signaling capacity due to an internal epitope present in the second framework of stereotyped IgHV that can be abrogated by using a BCR signaling inhibitor [15], an incapacity of the ER to release Ca^{2+} due to an inhibitory interaction between Bcl-2 (overexpressed in B-CLL cells) and the endoplasmic InsP_{2,R} [16], and last but not least an incompletely characterized BCR independent Ca^{2+} pathway recently described in B-CLL cells [17, 18]. Ca^{2+} deregulations in B-CLL cells and their correlation with disease evolution and severity are far from being fully understood. Reversing specific changes in deregulated Ca^{2+} fluxes may also represent new therapeutic opportunities to answer unmet needs in CLL treatment.

In this study we deciphered Ca^{2+} entry deregulation in B-CLL cells and tested whether BCR-dependent or BCR-independent Ca^{2+} entry would be relevant in CLL outcome. The latter was critical for disease progression, and we therefore analyzed and characterized a novel Ca^{2+} signaling pathway, referred to as constitutive Ca^{2+} entry (CE), which is triggered by STIM1 located at the plasma-membrane (STIM1_{PM}). Interestingly, we demonstrated that blocking CE with an anti-STIM1 monoclonal antibody (mAb) presents innovative therapeutic perspectives in CLL.

**Materials and methods**

**CLL population**

Clinical information was retrospectively obtained from 74 untreated patients diagnosed with CLL according to the World Health Organization (WHO) classification [19], and 13 healthy volunteers at the Brest University Hospital. Disease assessment included Binet stage determination, progression free survival (PFS), treatment free survival (TFS), CD38 expression, lymphocyte counts, lymphocyte doubling time (LDT), cytogenetic risk-status, and IgHV mutational status, which were performed as previously described [20]. Consent was obtained from all individuals and the protocol approved by the Ethical Board at the Brest University Hospital (clinicaltrials: NCT03294980; cohort OFICE; CRB Biobank collection 2008–2014), in accordance with the Declaration of Helsinki.

**Sample preparation and flow cytometry**

Peripheral blood mononuclear cells (PBMC) were isolated from whole blood by Ficoll-Hypaque density gradient centrifugation (Eurobio, Courtaboeuf, France) and B cells were further enriched using the Pan B-cell Isolation Kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Cell purity was assessed by fluorescence-activated cell sorting (FACS) analysis and was over 95% for B cells (CD19+).

All monoclonal antibodies (mAb) were from Beckman-Coulter (Brea, CA, USA) unless specified: FITC-conjugated anti-IgM (clone: SA-D4), cyanin (Cy)5.5-conjugated anti-CD38 (LS198.4.3), electron coupled dye (ECD)-labelled anti-CD5 (1A4CD27) mAbs with saturating concentrations were overexpressed using the Pan B-cell Isolation Kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Cell purity was assessed by fluorescence-activated cell sorting (FACS) analysis and was over 95% for B cells (CD19+).

All monoclonal antibodies (mAb) were from Beckman-Coulter (Brea, CA, USA) unless specified: FITC-conjugated anti-IgM (clone: SA-D4), cyanin (Cy)5.5-conjugated anti-CD38 (LS198.4.3), electron coupled dye (ECD)-labelled anti-CD5 (BL1a), allopheocyanin (APC)-conjugated anti-CD19 (J4–119), Pacific blue (PB)-conjugated anti-CD21 (1A4CD27) mAbs with saturating concentrations were incubated for 10 min at RT with 10 μl of PBS-washed blood. Versalyse solution (Beckman- Coulter) was added for 10 min in order to lyse red blood cells. The
determination of the mean fluorescence intensity (MFI) of all markers required a minimum of 5000 events. The results were standardized to those obtained with isotype controls. Data were analysed using Kaluza 1.5 software (Beckman-Coulter).

For intracellular staining, preliminary fixation and permeabilization were performed with the cytotox/cytoperm kit (BD Biosciences) followed by a 30 min incubation at 4 °C with Phycyo-Erythrin (PE)-conjugated anti-STIM1 (Gok, BD Biosciences), PC7-conjugated anti-CD19 and APC-AF700-conjugated anti-CD5 mAbs. The same protocol was applied for plasma membrane STIM1PM with the omission of the permeabilization step. In the transfection experiments a polyclonal rabbit anti-human Orai1 Ab (Sigma-Aldrich, Saint-Louis, MO) or anti-TRPC1 Ab (Alomone, Jerusalem, Israel) were used after the permeabilization step, and mAb staining was assessed with a FITC-conjugated goat anti-rabbit IgG (Jackson Immunoresearch, Ely, UK). To assess PLCγ2 phosphorylation, 5 × 10^5 cells were fixed and permeabilized with cold 80% methanol solution during 30 min. After 2 washes in PBS-BSA 0.05%, APC-conjugated anti-pPLCγ2 mAb (clone K86–689.37, BD Biosciences) was added.

**Effect on cell viability**

For each patient, B-CLL cells were incubated 48 h in 24-well plates at 37 °C with either (i) 10 μg/ml murine IgG2a (Biolegend, San-Diego, CA) (ii) 10 μg/ml anti-STIM1 (Gok), (iii) 10 μg/ml RTX (Roche, Paris, France), or (iv) 2x10μg/ml anti-STIM1 + RTX. All cultures were set at 5 × 10^5 B cells/mL in RPMI-1640 (Sigma-Aldrich) supplemented with 2 mM L-glutamine, antibiotics, and 20% of decomplemented normal human serum AB (Invitrogen, Carlsbad, CA). B cells were recovered, washed and stained for 15 min with FITC-conjugated annexin-V (AV) / propidium iodide (PI) and AF700-conjugated anti-CD19 antibody according to the Beckman-Coulter apoptosis kit protocol. The decrease in the percentage of live cells (CD19+ AV-PI-) was recorded.

**Calcium entry recording**

For CE measurements, B cells were loaded with 2 μM Fura-2/AM dye (Molecular Probes, Leiden, Netherlands) and 2 μM Pluronic acid (Gibco, Waltham, MA) for 30 min at 37 °C in a medium containing: 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM HEPES, 10 mM Glucose with an 7.4-adjusted pH (Buffer A) supplemented with 5 mM CaCl2. Cells were washed and left to attach in the same buffer on 12 mm Cell-Tak (Corning, NY) precoated coverslides for 20 min, allowing the de-esterification of the dye. Fura-2 was excited alternatively at 340 and 380 nm (Polychrome V, TILL photonics), and fluorescence emission was recorded at 510 nm using a fluorescence microscope (IX71, Olympus) equipped with a dichroic mirror (415DCLP) and a 14-bit CCD camera (ExiBlue, Qimaging). After the stabilization of basal fluorescence, the extracellular medium was replaced with Buffer A supplemented with 0.5 mM CaCl2 for 100 s and again with the original 5 mM CaCl2-containing Buffer A after curve stabilization. Excitation/emission ratio (F340nm/F380nm) was calculated for each time point and each cell with the Metafluor 6.3 Software (Universal Imaging, West Chester, USA). The amplitude of CE was calculated after normalization to the basal ratio (ΔF/F0), as the difference between average values of basal ratio measured in 5 mM external Ca2+ and the average ratio value in 0.5 mM Ca2+.

For anti-IgM and Thapsigargin (TG)-induced calcium entry, B cells were loaded in Buffer A containing 1.8 mM CaCl2 and 2 μM Fura-2/AM (Fura-2 QBT Kit, Molecular Devices) for 1 h at 37 °C in Cell-Tak precoated 96-well plates, and fluorescence acquisition (excitation 340 and 380 nm; emission 510 nm) was performed on the Flexstation 3 microplate reader with SoftMax Pro 5.4.5 software (Molecular Devices, San Josa, CA). For anti-IgM induced Ca2+ response, the extracellular medium was replaced with Buffer A supplemented with 10 mM CaCl2, before reading, and 10 μM of polyconal goat anti-human IgM (Jackson Immunoresearch) were injected after 150s. TG-induced ER Ca2+ release, extracellular medium was replaced with Buffer A supplemented with 100 μM EGTA just before starting the reading protocol. A stimulation with 2 μM of TG was performed after 100 s of recording, and 1.8 mM CaCl2 was added after 700 s in order to quantify SOCE entry. Ca2+ entry were quantified after value normalization (ΔF/F0) with the exception of basal Ca2+ concentrations estimated as the average of initial F340nm/F380nm values.

In selected experiments, 1 μM Brutinib (SelleckChem, Munich, Germany), 5 μM LY294002 (Sigma Aldrich), 2.5 μM Synta66 (Sigma Aldrich), DMSO, 10 μg/ml anti-STIM1 (clone GOK) or 10 μg/ml IgG2a mAb were added to the loading buffer.

**Transient transfection**

The small interfering RNAs (siRNA) targeting Orai1 (GCAAAGUCGCAAAUCUAAtt, Sigma), STIM1 (AGG UGGAGUGCAAUUAUAtt, Dharmaco, Lafayette, CO), TRPC1 (U7311), and the control siRNA (4390843) were purchased from Ambion unless specified and transfected in B-CLL cells from 3 CE+ CLL patients by nucleofection (Lonza, Basel, Switzerland) as previously described [17, 21]. After a 48 h-incubation, the knock-down was controlled by flow cytometry and intracellular Ca2+ analysis was performed.
Western blot
Protein extraction was performed by incubating $10^7$ B cells for 30 min on ice in a lysis buffer containing: 20 mM Tris HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X100, 2.5 mM Na’ pyrosodium tetraphosphate, 1 mM glycophosphate, 1 mM Na’ orthovanadate, 1 μg/ml leupeptin and protease inhibitor cocktail (Roche). Protein extracts were sonicated and centrifuged for 12 min at 16,000 g. The protein concentration of the cell lysates was determined using the micro-bicinchoninic acid assay, and 50 μg were run on SDS-PAGE (10% polyacrylamide gels) in denaturing conditions, and transferred onto PVDF membrane sheets (Bio-Rad, Hercules, CA). After unbound sites were blocked, blots were probed overnight with 5% fat milk in PBS, 0.1% tween 20, and either mouse monoclonal anti-STIM1 (GOK: I:1000; Sigma Aldrich), mouse monoclonal anti-TRPC1 (E6; I:1000; Santa Cruz, Dallas, TX) or mouse monoclonal anti-GAPDH antibody (6C5; I:10,000; Abcam, Cambridge, UK). Washed blots were incubated with Horseradish Peroxidase (HRP)-conjugated goat anti-mouse or rabbit IgG Ab (I:10,000; Abcam). Image acquisition was performed on a Chemi-Smart 5100 system (Vilber-Lourmat) with the Chemi-Capt 5000 software and analysed on Image J. All results were normalized upon GAPDH quantification.

Statistical analysis
Continuous data are described as mean ± standard error of the mean (SEM). Following normality and equality of variance tests, nominal values were compared to controls using the student’s t test or alternatively by using a nonparametric test (Mann-Whitney rank sum test). Differences among groups were analyzed by one-way ANOVA in a non-parametric test and the Dunn’s test was used for post-hoc comparisons. For categorical data the Fisher’s exact test was used, and for correlation analysis the Pearson’s coefficient r was calculated. The profile likelihood method using a Cox regression model of PFS was used in univariate analysis to determine the optimal threshold and stratify patients into two groups as previously described [22]. PFS, TFS and LDT analyses were next performed using Kaplan–Meier curves and prognosis differences between groups were assessed with a log-rank test. Receiver operating curves (ROC) were generated to determine the area under the curve (AUC) and the optimal cut-off values were chosen by using the upper left corner value (100% specificity). P values under 0.05 were considered significant. Statistical analyses and the correlation matrix were performed using GraphPad Prism 7.0a (La Jolla, CA).

Results
Constitutive Ca$^{2+}$ entry is higher in unstimulated B-CLL cells from patients with progressive disease
As deregulation in Ca$^{2+}$ signaling is an important hallmark of B-CLL cells, and suspected to vary during CLL disease progression [2], Ca$^{2+}$ entry in the absence of BCR engagement, designated as CE, was evaluated in resting B-CLL cells. To this end 30 untreated CLL patients were selected and, as reported in Fig. 1a, CE was significantly enhanced in a subset of B-CLL cells when compared to B cells from 8 healthy controls ($\Delta F/F_0$: 0.10 ± 0.01 in B-CLL cells versus 0.06 ± 0.01 in controls, $P = 0.03$). CLL patients were further dichotomized into CE+ (high levels) versus CE- (normal/low levels) using the profile likelihood method in a Cox regression model of PFS for optimal cut-off identification (cut-off = 0.083).

Next, and according to this dichotomy, the Kaplan-Meier log-rank analysis revealed, for those CE+ CLL patients ($n = 16$), a significant difference with regards to parameters associated with disease outcome such as PFS ($P = 0.001$; Fig. 1b), TFS ($P = 0.003$; Fig. 1c) and LDT ($P = 0.02$; Fig. 1d). In addition, the Binet status ($P = 0.0002$) and lymphocytosis ($P = 0.003$) were associated with an elevated CE, which was not the case for the cytogenetic risk status, IgHV mutational status, and CD38 positivity (Table 1, left part).

Constitutive Ca$^{2+}$ entry is independent from proximal BCR signaling and BCR co-activators
One step further, to test BCR pathway dependence in CE+ B-CLL cells, the BCR capacity to mobilize Ca$^{2+}$ was tested within B-CLL cells from 16 CE+ CLL patients, 13 CE- CLL patients, and 13 healthy controls (Fig. 2a and Additional file 2: Figure S2). As previously described [2, 3], Ca$^{2+}$ mobilization in response to BCR engagement was reduced in B-CLL cells when compared to controls ($P = 0.002$ for both CE subgroups), however no difference was observed when comparing the two CE subgroups within CLL patients. Interestingly, by conducting a bivariate analysis of PFS on both CE and IgM Ca$^{2+}$ mobilization, we further observed that CLL patients with disease progression were restricted to CE+/IgM+ ($n = 11$) and CE+/IgM- ($n = 5$) CLL patients but not to CE-/+IgM+ ($n = 4$) and CE-/+IgM- ($n = 9$) CLL patients ($P = 0.006$, Fig. 2b). To dissect heterogeneity between the 4 subgroups of patients (Additional file 2: Table S1), we next examined whether these differences resulted from differential expression of the membrane surface (s) IgM, slgD, and co-receptors (CD19, CD21, CD38, and CD5). No differences were observed between the 4 subgroups for these markers that participate or modulate the proximal BCR signaling. As well, no differences were reported when considering CE+ and CE- CLL patients.
Accordingly, we concluded that there is independence of CE from proximal BCR signaling and BCR co-activators.

**Constitutive Ca\(^{2+}\) entry is independent from an autonomous BCR pathway**

Since CE could be attributable to an antigen-independent autonomous BCR pathway [15], this Ca\(^{2+}\) entry was recorded in the presence of two BCR signalosome inhibitors Ibrutinib, a covalent inhibitor of BTK, and LY294002, a selective inhibitor of PI3K\(\delta\). As shown in Fig. 2c/d, CE+ B-CLL cells from 3 patients were selected and CE was unaffected by the addition of the BCR signaling inhibitors. In parallel and as a positive control, the Ibrutinib and LY294002 capacity to inhibit Ca\(^{2+}\) response following BCR activation was demonstrated (Fig. 2e/f). Such a concept was further reinforced by the analysis of basal pPLC\(\gamma\)2, an indicator of BCR signalosome activation, in resting B-CLL cells showing that pPLC\(\gamma\)2 levels were similar between the CE+ and CE- CLL subgroups (Additional file 2: Table S1).

**Constitutive Ca\(^{2+}\) entry is correlated with basal Ca\(^{2+}\) levels and independent from SOCE**

Next, 29 B-CLL cells (10 CE-/IgM-, 4 CE+/IgM+, 4 CE+/IgM- and 11 CE+/IgM+) were selected and a correlation matrix was performed for all in order to compare CE with (i) the basal intracellular Ca\(^{2+}\) level estimated by the initial F340/380 ratio, (ii) the anti-IgM Ca\(^{2+}\) response; (iii) the ER Ca\(^{2+}\) release by thapsigargin (TG), an inhibitor of the ER Ca\(^{2+}\) ATPase pumps, that artificially and maximally deplete Ca\(^{2+}\) stores in the absence of extracellular Ca\(^{2+}\); and (iv) the TG SOCE response observed after Ca\(^{2+}\) refilling.

Results from the correlation matrix were effective to highlight two groups of Ca\(^{2+}\) responses in B-CLL cells (Additional file 2: Figure S3A/B). First an association based on the correlation observed between CE and the
First, specific blockade of Orai1 channels with S66 at 25 μM significantly blocked CE (P = 0.03), the anti-IgM and Tg SOCE response in CE+ B-CLL cells. Second, control conditions (Fig. 3a,b) and data not shown), second, and another way in which to further support our hypothesis, was to reduce the expression of STIM1, Orai1, and TRPC1 (FACS representations of STIM1, Orai1, and TRPC1 was seen at the protein level when using specific siRNAs in CE+/IgM+ B-CLL cells compared to control conditions (Fig. 3a/b and data not shown). In contrast to the negative siRNA control, a reduction in STIM1 expression by Western-blot TRPC1 and STIM1 expression by Western-blot not to be significant (P = 0.03) and TG SOCE (P = 0.05) and the 85 kDa glycosylated isoform that were overexpressed in CE+ B-CLL cells. STIM1 analysis by WB reveals higher expression of both the 75 kDa non-glycosylated isoform and the 85 kDa glycosylated isoform that were overexpressed in CE+ B-CLL cells (P = 0.03).

The pool of STIM1 located in the plasma membrane (STIM1 PM) controls CE. Since glycosylation is required for STIM1 localization at the plasma membrane (STIM1 PM), controls CE and contributes to its enhancement in CE+ B-CLL cells. To address the possibility that STIM1 PM controls CE, we analyzed CE obtained from the same patient with CE-bearing B-CLL cells. Immunofluorescence staining for STIM1 PM revealed higher expression of STIM1 PM in CE+ compared to CE- B-CLL cells (Fig. 3c). As a result, CE was reduced in the presence of specific siRNA to Orai1, TRPC1 and STIM1 (P = 0.001), but not CE with an IgM and Tg SOCE response (data not shown). Second, and another way in which to further support our hypothesis, was to reduce the expression of STIM1, Orai1, and TRPC1 (FACS representations of STIM1, Orai1, and TRPC1 was seen at the protein level when using specific siRNAs in CE+/IgM+ B-CLL cells compared to control conditions (Fig. 3a/b and data not shown). In contrast to the negative siRNA control, a reduction in STIM1 expression by Western-blot TRPC1 and STIM1 expression by Western-blot not to be significant (P = 0.03) and TG SOCE (P = 0.05) and the 85 kDa glycosylated isoform that were overexpressed in CE+ B-CLL cells. STIM1 analysis by WB reveals higher expression of both the 75 kDa non-glycosylated isoform and the 85 kDa glycosylated isoform that were overexpressed in CE+ B-CLL cells (P = 0.03).
(STIM1<sub>PM</sub> quantification). In agreement with WB results, FACS analysis revealed that both total-STIM1 and STIM1<sub>PM</sub> were increased in CE+ B-CLL cells (\(P = 0.01\) and \(< 10^{-4}\), respectively), and their levels correlated with CE amplitude (\(P = 0.01\) both, Fig. 5b). A ROC analysis was performed in order to establish the cut-off for positivity (Fig. 5b left). We next sought to determine STIM1<sub>PM</sub> involvement in CE regulation, and this was tested by exploring the capacity of the anti-STIM1 mAb (GOK, 10 μg/mL) to inhibit CE. In contrast to the IgG2a isotype control mAb that had no effect on CE (Fig. 5c), the anti-STIM1 mAb inhibits CE (\(P = 0.03\)), while no effects were reported on the anti-IgM Ca<sup>2+</sup> response, TG ER Ca<sup>2+</sup> release and TG SOCE responses (Fig. 5d and Additional file 2: Figure S4B). This is in agreement with the observed correlation between STIM1<sub>PM</sub> levels and basal Ca<sup>2+</sup> but not with TG ER Ca<sup>2+</sup> release and IgM/ TG SOCE results (Additional file 2: Figure S4A).

Fig. 2 Constitutive calcium entry (CE) is independent from anti-IgM capacity to induce Ca<sup>2+</sup> signaling in chronic lymphocytic leukemia (CLL).

a - Normalized ratio of peak to baseline Ca<sup>2+</sup> flux in response to anti-IgM stimulation of healthy control (n = 13, Ctrl), CE- CLL (n = 13) and CE+ CLL (n = 16) samples. b - Bivariate analysis by Kaplan-Meier curves of Ca<sup>2+</sup> signaling in the context of CLL subsets according to the CE (+/-) and anti-IgM capacity to induce Ca<sup>2+</sup> signaling (IgM +/-). A Cox regression model of progression free survival (PFS) was used to dichotomize CLL patients in CE- and CE+, on one hand, and IgM- and IgM+, on the other hand. c/d - The effects of Ibrutinib (BTK inhibitor, 2.5 μM) and LY294002 (PI3K inhibitor, 5 μM) on CE in CE+/IgM+ B-CLL samples (n = 3). e/f - The effects of Ibrutinib (BTK inhibitor) and LY294002 (PI3K inhibitor) on anti-IgM capacity to induce Ca<sup>2+</sup> signaling in CE+/IgM+ B-CLL samples (n = 3). P values are indicated when significant.
Altogether this reinforces our hypothesis that CE and basal Ca$^{2+}$ are regulated by STIM1 PM and supported by Orai1 and TRPC1 channels in a unique and alternative influx pathway distinct from SOCE and downstream the BCR-InsP3R pathway.

**STIM1PM as a valuable therapeutic target**

As CE determination is difficult to manage in routine practice, we further compared the patient’s characteristics according to their plasma membrane STIM1 status in 74 untreated CLL that included those tested for Ca$^{2+}$ signaling. As depicted in the Kaplan-Meyer curves (Fig. 6a), the CLL STIM1 PM high subgroup had shorter PFS and TFS ($P = 0.0007$ and $P = 0.02$, respectively). Characteristics of STIM1 PM high and low patients are presented in Table 1 (right part) showing that lymphocytosis ($p = 0.05$), but not the other parameters tested, was increased in the CLL STIM1 PM high subgroup.

Finally and as the initial descriptions of STIM1 PM were related to the control of cell survival [27, 28], we next decided to test the neutralizing capacity of the anti-STIM1 mAb clone GOK to control B-CLL cell survival when used alone or in combination with RTX, an anti-CD20 mAb (Fig. 6b). Used alone GOK and RTX did not reduce in vitro B-CLL cell survival as compared to the controls, but in contrast the RTX + GOK combination significantly reduced cell viability in the STIM1 PM high subgroup (50.4 ± 6.4% with IgG2a versus 23.0 ± 4.7% with RTX + GOK, $P = 0.03$), an effect which was not significant in the STIM1 PM low subgroup (33.5 ± 6.5% with IgG2 versus 20.3 ± 4.7% with RTX + GOK).

**Discussion**

The overall data add new support to the critical role played by the Ca$^{2+}$ signaling in CLL outcome, and describe for the first time a novel STIM1 PM-dependant and constitutively active Ca$^{2+}$ entry, independent from BCR signaling, and that constitutively active CE can be modulated and targeted by an anti-STIM1 mAb. We found that both CE and STIM1 PM are clinically relevant in CLL and their determinations present important prognostic value.

Several reports have demonstrated altered Ca$^{2+}$ signaling in CLL B cells and with the paradox that Ca$^{2+}$ mobilization is altered in “anergic” CLL B cells from non-progressive patients, while a response is reported in CLL B cells from patients with disease progression as
observed in our study [2, 3]. Moreover and based on the strong correlation observed between CE and basal cytosolic Ca\(^{2+}\) concentrations in this study, we were able to extend the observation performed by Muggen and colleagues who have described elevated basal Ca\(^{2+}\) concentrations in B-CLL cells in contrast to normal B cells [14]. Our study also supports that CE and the elevated level of basal Ca\(^{2+}\) reported in B-CLL cells are, in fact, independent from the BCR-PLC\(\gamma_2\)-InsP\(_3\)R pathway and are instead related to an enhanced CE and are independent from store depletion. In contrast, Duhren-Von Minden and colleagues have associated the elevated basal Ca\(^{2+}\) signaling downstream Syk phosphorylation in CLL B cells to an antigen-independent recognition of the BCR framework domains (FR2 or FR3), or alternatively through an occupation of the BCR with repetitive motifs [15]. Importantly, blocking the BCR pathway with the BTK inhibitor ibrutinib or with the PI3K inhibitor LY294002 did not alter CE or the basal Ca\(^{2+}\) level (data not shown) which is in agreement with Muggen report who failed to associate the basal Ca\(^{2+}\) level in CLL B cells with the FR2/3 amino-acid sequence. Based on the report of Le Roy and colleagues who detected pSyk at a basal level in IgM+ responder patients, it could be proposed that blocking pSYK controls both CE and the IgM response in CE+/IgM+ responder patients, an hypothesis that needs to be tested as well as the capacity of Syk to phosphorylate STIM1 [2, 3].

STIM1 was initially identified as a plasma membrane protein [25], and more recently STIM1\(_{PM}\) was associated with the regulation of a store independent Ca\(^{2+}\) entry pathway activated by arachidonic acid [26] and to SOCE in platelets [29]. Similarly and although STIM1 is predominantly located in the ER in normal B cells, we found that CE+ B-CLL cells express a substantial amount of STIM1\(_{PM}\) and Orai1 as well as an enhanced expression of TRPC1. This is important because STIM1\(_{PM}\) can interact with Orai1 or TRPC1, two Ca\(^{2+}\) channels activated in CE+ B-CLL cells as demonstrated by using specific siRNAs and in agreement with the Chen KT et al. report [30]. STIM1 deregulation in B-CLL cells needs further exploration as it may be related to defective transcriptional control by DNA methylation and/or microRNAs [31, 32], and/or is related to post-translational modifications such as glycosylation and/or phosphorylation known to affect STIM1 localization and properties [24, 33], as these processes are altered during CLL evolution [34].
The clinical success of RTX in monotherapy is limited in CLL and, in order to improve its efficacy, RTX is associated with chemotherapy (RFC) or with BCR inhibitors (Ibrutinib, Idelalisib, venetoclax), however relapses and side-effects remain important suggesting a need to develop new therapeutical options and in particular to combine RTX with new drugs targeting a non BCR survival pathway [35, 36].

Consistent with the notion that CE is important for disease outcome and STIM1PM for CE, we demonstrated that pre-incubation of cells with antibodies targeting STIM1PM reverses B-CLL cell capacity for CE and in turn impairs cell survival when associated with RTX. Therefore, we propose to use anti-STIM1 mAb targeting STIM1PM and CE as a new innovative therapeutic option for CLL. An additive/synergic effect of RTX or BCR inhibitors with CE inhibitors, such as anti-STIM1 mAb, should be addressed in future studies.

Relevant limitations of our study include the following: (i) a small sample size used to analyze Ca\textsuperscript{2+} entry in CLL B cells; (ii) the use of samples from a cross-sectional and monocentric center; and (iii) a bias due to the selection of untreated patients. However and to reduce these limitations, a large panel of approaches (e.g. Ca\textsuperscript{2+} signaling, siRNAs, specific inhibitors, FACS, WB) has been used in order to demonstrate that STIM1 and in particular STIM1PM controls CE in CLL B cells from patients with progressive disease. The selection of untreated patients for this study represents also an advantage as drug exposure may affect the analysis of Ca\textsuperscript{2+} entry, as observed in vitro with ibrutinib. Future studies are however mandatory in order to study whether variations

![Fig. 5](#)
in Ca\(^{2+}\) entry and Ca\(^{2+}\) actor variations vary following treatment introduction and in those patients who relapse.

**Conclusion**

In CLL the involvement of Ca\(^{2+}\) signaling deregulation in cancer cell progression is well established, but the identification of mechanisms controlling Ca\(^{2+}\) entry are poorly understood. In the present work, an extensive analysis of the Ca\(^{2+}\) entry in CLL cells was performed, revealing, in patients with progressive disease, the implication of a constitutive and BCR-independent Ca\(^{2+}\) entry pathway. Next, it was further observed that a pool of STIM1 present in the plasma membrane characterizes tumor progression and controls constitutive Ca\(^{2+}\) entry. Finally, the capacity of an anti-STIM1 mAb to block constitutive Ca\(^{2+}\) entry and to reduce in vitro CLL cell viability, when associated with Rituximab, was reported within the high STIM1\(_{PM}\) CLL subgroup. This supports the idea that targeting STIM1\(_{PM}\) and therefore constitutive Ca\(^{2+}\) entry represents a new 1st in class therapeutic pathway in leukemia treatment. The potential use of mAb targeting STIM1\(_{PM}\) in cancer therapy that can be used alone or in synergy with existing drugs needs to be further evaluated.

**Additional files**

**Additional file 1: Figure S1.** Two pathways control Ca\(^{2+}\) signaling in B cells from patients with chronic lymphocytic leukemia. In the BCR-induced store operated Ca\(^{2+}\) entry pathway, B cell receptor (BCR) interaction with the antigen results in the formation of the signalosome consisting of an active complex composed of the tyrosine kinases Lyn and Syk, B-cell linker protein (BLNK), Bruton-tyrosine-kinase (BTK), phospholipase C gamma 2 (PLC\(_{γ2}\)), and phosphatidylinositol-4,5-bisphosphate 3-kinase 6 (PI3K\(_δ\)) that phosphorylates CD19. Signalosome activation cleaves the membrane phospholipid phosphatidyl inositol 4,5-biphosphate (InsP2) into diacylglycerol (DAG) and inositol 1,4,5-triphosphate (InsP3), which subsequently, through binding to the endoplasmic reticulum (ER) IP3 receptor (InsP3R), mobilizes initially Ca\(^{2+}\) from stores and secondarily extracellular Ca\(^{2+}\) through the interaction between the multimerized reticular stromal interaction molecule 1 (STIM1\(_{ER}\)) and the plasma-membrane Orai1 channel. In the constitutive Ca\(^{2+}\)
Written informed consent was obtained from all of the patients. Consent for publication was read and approved by all authors.

Abbreviations

BCR: B cell receptor; Ca\textsuperscript{2+}: Calcium; CE: Constitutive Ca\textsuperscript{2+} entry; CLL: Chronic lymphocytic leukemia; FACS: Fluorescence-activated cell sorting; IgM: Immunoglobulin M; InsP3: Inositol 1,4,5-triphosphate; InsP3R: Inositol 1,4,5-triphosphate receptor; LDLT: Lymphocyte doubling time; mAb: Monoclonal antibody; NFAT: Nuclear factor of activated T-cells; NFATc: Nuclear factor of activated T-cells cytoplasmic domain; NFATp: Nuclear factor of activated T-cells protein; PFS: Progression free survival; PBS: Phosphate buffer saline; PEG: Polyethylene glycol; PFA: Paraformaldehyde; PGE2: Prostaglandin E2; PLB-1: Protein tyrosine phosphatase, type 1B; SOCE: Store-operated Ca\textsuperscript{2+} entry; STIM1: Stromal interaction molecule 1; TG: Thapsigargin; TRPC1: Transient receptor potential canonical 1; TFS: Treatment free survival; TGFβ: Transforming growth factor β; TLR: Toll-like receptor; TRAIL: TNF-related apoptosis-inducing ligand; TUNEL: TdT-mediated dUTP nick end-labelling; t-PA: Tissue-type plasminogen activator; UCHL1: Ubiquitin C-terminal hydrolase L1; Urea: Urea; WBC: White blood cells; WEG: World Health Organization; Wnt: Wnt signaling pathway; XBP1: X-box binding protein 1.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1INSERM U1227 B lymphocytes and autoimmunity, University of Brest, Brest, France. 2INSERM U1069, N2C, 37032, University of Tours, Tours, France. 3C-CGO network from “Canceropole Grand Ouest”, Brest, France. 4Laboratory of Immunology and Immunotherapy, CHRU Brest Morvan, Brest, France.

Received: 30 January 2019 Accepted: 2 April 2019

Published online: 23 April 2019

References

1. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wienda WG, et al. Chronic lymphocytic leukemia. Nat Rev Dis Primers. 2017;3:16096.
2. Le Noy C, Deglesne PA, Chevalier N, Beitar T, Ecche V, Quetlett M, et al. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia. Blood. 2012;120(2):356–65.
3. Nedelce S, Renaudineau Y, Bordon A, Berthou C, Porashvili N, Lydyard PM, et al. B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. J Immunol. 2005;174(6):3749–56.
4. Baba Y, Kurotsuki T. Physiological function and molecular basis of STIM1-mediated calcium entry in immune cells. Immunol Rev. 2009;231(1):174–88.
5. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol. 2007;7(10):690–702.
6. Mukherjee S, Karakal A, Debant M, Buscaligl P, Renaudineau Y, Mignen O, et al. Molecular dynamics simulations of membrane-bound STIM1 to investigate conformational changes during STIM1 activation upon calcium release. J Chem Inf Model. 2017;57(2):335–44.
7. Vaeth M, Maus M, Klein-Hessling S, Freinkman E, Yang J, Eckstein M, et al. Store-operated Ca2+ entry controls clonal expansion of T cells through metabolic reprogramming. Immunity. 2017;47(4):664–79 e6.
8. Vaeth M, Eckstein M, Shaw PJ, Kozhaya L, Yang J, Berberich-Siebelt F, et al. Store-operated Ca2+ entry in follicular T cells controls humoral immune responses and autoimmunity. Immunity. 2016;44(6):1350–64.
9. Debant M, Hemon P, Brugadeau C, Renaudineau Y, Mignen O. Calcium signaling and cell fate: how can Ca2+ signals contribute to wrong decisions for chronic lymphocytic leukemia B cell outcome? Int J Dev Biol. 2015;59(7–8):337–47.
10. Hemon P, Renaudineau Y, Debant M, Le Goux N, Mukherjee S, Brooks W, et al. Calcium Signaling: From Normal B Cell Development to Tolerance Breakdown and Autoimmunity. Clin Rev Allergy Immunol. 2017;53(2):141–65. https://doi.org/10.1007/s12016-017-8667-6. Review. PubMed PMID: 28500564.
11. Baba Y, Kurotsuki T. Role of calcium signaling in B cell activation and biology. Curr Top Microbiol Immunol. 2016;398:143–74.
12. Yarkoni Y, Cambier JC. Differential STIM1 expression in T and B cell subsets suggests a role in determining antigen receptor signal amplitude. Mol Immunol. 2011;48(15–16):1851–8.
13. D’Avola A, Drennan S, Tracy I, Henderson I, Ciocchi L, Larrazay M, et al. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood. 2016;128(8):816–26.
14. Muggen AF, Pillai SY, Kil LP, van Zelm MC, van Dongen JJ, Hendriks RW, et al. Basal ca2+ signaling is particularly increased in mutated chronic lymphocytic leukemia. Leukemia. 2015;29(2):321–8.
15. Duhren-von Manden M, Ubelhart R, Schneider D, Wossing T, Bach MP, Buchner M, et al. Chronic lymphocytic leukemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7421):309–12.
16. Zhong F, Harr MW, Bullyung G, Monaco G, Pays J, De Smedt H, et al. Induction of ca2+-driven apoptosis in chronic lymphocytic leukaemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood. 2011;117(10):2924–34.
17. Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, et al. CDS expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. Cell Mol
18. Vaistti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, et al. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia. 2015;29(2):356–68.

19. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. OMS ed. Tumours WCo, editor 2008:

20. Bagacean C, Tempescul A, Patiu M, Fetică B, Bumbea H, Zdrenghea M. Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report. Onco Targets Ther. 2017;10:31–4.

21. Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, et al. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol. 2011;186(8):4835–44.

22. Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, et al. Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion. Clin Epigenetics. 2017;9:122.

23. Chantome A, Potier-Carteau M, Clarysse L, Fromont G, Marionneau-Lambot S, Gueguinou M, et al. Pivotal role of the lipid raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 2013;73(3):4852–61.

24. Williams RT, Senior PV, Van Stekelenburg L, Layton JE, Smith PJ, Dziadek MA. Stromal interaction molecule 1 (STIM1), a transmembrane protein with growth suppressor activity, contains an extracellular SAM domain modified by N-linked glycosylation. Biochim Biophys Acta. 2002;1596(1):131–7.

25. Shuttleworth TJ, Thompson JL, Mignen O. STIM1 and the noncapacitative ARC channels. Cell Calcium. 2007;42(2):183–91.

26. Mignen O, Thompson JL, Shuttleworth TJ. STIM1 regulates Ca2+ entry via arachidonate-regulated Ca2+--selective (ARC) channels without store depletion or translocation to the plasma membrane. J Physiol. 2007;579(Pt 3):703–15.

27. Sabbioni S, Barbanti-Brodano G, Croce CM, Negri M. GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. Cancer Res. 1997;57(20):4493–7.

28. Oritani K, Kincade PW. Identification of stromal cell products that interact with pre-B cells. J Cell Biol. 1996;134(3):771–82.

29. Jardin I, Lopez JJ, Redondo PC, Salido GM, Rosado JA. Store-operated Ca2+ entry is sensitive to the extracellular Ca2+ concentration through plasma membrane STIM1. Biochim Biophys Acta. 2009;1793(10):1614–22.

30. Cheng KT, Liu X, Ong HL, Swaim W, Ambudkar IS. Local Ca(i)2+ entry via Orai1 regulates plasma membrane recruitment of TRPC1 and controls cytosolic Ca(i)2+ signals required for specific cell functions. PLoS Biol. 2011;9(3):e1001025.

31. Sabbioni S, Veronese A, Trubia M, Taramelli R, Barbanti-Brodano G, Croce CM, et al. Exon structure and promoter identification of STIM1 (alias GOK), a human gene causing growth arrest of the human tumor cell lines G401 and RD. Cytogenet Cell Genet. 1999;86(3–4):214–8.

32. Zhang Z, Liu X, Feng B, Liu N, Wu Q, Han Y, et al. STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer. Oncogene. 2015;34(37):4808–20.

33. Sabbioni S, Veronese A, Trubia M, Taramelli R, Barbanti-Brodano G, Croce CM, et al. Exon structure and promoter identification of STIM1 (alias GOK), a human gene causing growth arrest of the human tumor cell lines G401 and RD. Cytogenet Cell Genet. 1999;86(3–4):214–8.

34. Manji SS, Parker NJ, Williams RT, van Stekelenburg L, Pearson RB, Dziadek M, et al. STIM1: a novel phosphoprotein located at the cell surface. Biochim Biophys Acta. 2000;1481(1):147–55.

35. Bordron A, Bagacean C, Mohr A, Tempescul A, Bendaoud B, Deshayes S, et al. Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. Oncotarget. 2018;9(60):31590–605.

36. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92(9):946–65.